Revised SPC: Halaven (eribulin) 0.44 mg/ml solution for injection -

Revised SPC: Halaven (eribulin) 0.44 mg/ml solution for injection
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Cancers | Haematological disorders | Later life | Paediatric and neonatal medicine
Summary
SPC revised with the new licensed indication for adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.
UKMi comment
The SPC now also highlights that no dose adjustments are recommended for the elderly population and that the safety and efficacy of eribulin in children from birth to 18 years of age have not yet been established in soft tissue sarcoma.
Related links: